-+ 0.00%
-+ 0.00%
-+ 0.00%

VANDA PHARMACEUTICALS: PRIORITY REVIEW WOULD ESTABLISH 6-MONTH REVIEW CYCLE, POTENTIAL IMSIDOLIMAB FDA APPROVAL FOR GPP TREATMENT AS EARLY AS MID-2026

路透·12/15/2025 12:00:02

登录查看新闻详情